Stocks
Lipocine Inc.LPCN
NASDAQHealthcareBiotechnology$1.44
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing oral therapies for central nervous system and liver disorders, with a focus on prodrug-based formulations. Its lead candidate targets hepatic encephalopathy, and investors track it for its pipeline milestones and regulatory updates.
52W Range: $1.40-$12.37
Congressional Interest in Lipocine Inc. (LPCN)
No congressional trades have been disclosed for Lipocine Inc. (LPCN) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading LPCN?
No congressional trades found for this stock.